Showing results (61-70 of 167) with videos related to
Sort By:
Pageof 17
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 12, 2016
Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung AdenocarcinomasM C Pietanza, Matthew D Hellmann, John J Fiore, et al.Cancer Cell|June 13, 2018
Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade ActivityRoberta Zappasodi, Sadna Budhu, Matthew D Hellmann, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 4, 2020
Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumabMichael Offin, Narek Shaverdian, Andreas Rimner, et al.Journal for Immunotherapy of Cancer|June 1, 2022
Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancerMiguel Lopez de Rodas, Venkata Nagineni, Arvind Ravi, et al.Cancer Discovery|August 21, 2020
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint BlockadeQu Zhang, Jia Luo, Song Wu, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 20, 2021
CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 MinibodyMichael D Farwell, Raymond F Gamache, Hasan Babazada, et al.Cancer Cell|May 8, 2018
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung CancerMatthew D Hellmann, Margaret K Callahan, Mark M Awad, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 27, 2018
Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLCScott Gettinger, Matthew D Hellmann, Laura Q M Chow, et al.JTO Clinical and Research Reports|July 21, 2025
A Phase II Study of Cabozantinib in Patients With MET-Altered Lung CancersGuilherme Harada, Fernando C Santini, Clare J Wilhelm, et al.The Lancet. Respiratory Medicine|March 17, 2019
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 studyNatasha B Leighl, Matthew D Hellmann, Rina Hui, et al.Pageof 17